share_log

Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.

Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.

Cognition Therapeutics的股票在公司提供了關於輕度至中度阿爾茨海默症的第2期SHINE研究生物標誌物分析更新後交易價格上漲。
Benzinga ·  2024/11/25 20:45

Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.

Cognition Therapeutics的股價走高,此前該公司提供了針對輕度至中度阿爾茨海默氏病的SHINE二期研究的生物標誌物分析的最新情況。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論